| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Silexion Therapeutics Corp
13D/A
SLXN · G1281K122
|
1.3% |
6/26/2025
Event 6/26/2025
|
||||
| Wildcat Capital Management, LLC | 1.3% | |||||
| Wildcat Partner Holdings, LP | 1.3% | |||||
| Leonard A. Potter | 1.3% | |||||
| Schedule 13G · 1 security · passive | ||||||
|
Vicapsys Life Sciences, Inc.
13G
VICP · 92560A106
|
18.8% |
3/21/2025
Event 4/20/2020
|
||||
| Wildcat Capital Management, LLC | 18.8% | |||||
| Wildcat Partner Holdings, LP | 18.8% | |||||
| Leonard A. Potter | 18.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.